A coincidence of renal cell carcinoma and hematological malignancies

Sargın, Gökhan; Yavaşoğlu, İrfan; Doger, Firuzan Kacar; Kadıköylü, Gürhan

doi:10.1007/s12032-012-0316-7

Cited by 8 publications

(7 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is also an increased risk of RCC in patients with NHL that may be attributed to chemotherapy and radiation used in NHL treatment[ 2 , 3 , 11 , 12 ]. Additional etiologies for concurrent RCC and HM include viruses such as Epstein-Barr virus, Helicobacter pylori , and human T-lymphotropic virus-1 that have been implicated in lymphomas and carcinomas[ 2 , 8 ].…”

Section: Discussionmentioning

confidence: 99%

“…Several mechanisms have been proposed to account for concurrent RCC and HM, including genetic mutations common to both RCC and HM, hormonal or environmental factors, viral infections, prior cytotoxic chemotherapy or radiation for malignancy, and immune dysregulation[ 2 , 3 , 5 , 8 - 12 ]. It has been suggested that the first malignancy predisposes to the second through an immunomodulatory effect[ 1 - 4 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Concurrent renal cell carcinoma and hematologic malignancies: Nine case reports

Shields

Kalebasty

2020

WJCO

View full text Add to dashboard Cite

BACKGROUND The presence of renal cell carcinoma (RCC) and hematologic malignancies (HM) in the same patient is rarely observed. Three primary findings have been described in these patients, including male gender and lymphoid malignancy predominance, and the HM are usually diagnosed before or simultaneously with the RCC. There is a lack of evidence about clinical outcomes in this setting. We report the common characteristics of 9 patients diagnosed with concurrent RCC and HM and their clinical course and response to treatment. CASE SUMMARY Four (44%) patients were diagnosed with RCC prior to the HM, the diagnosis was simultaneous in 4 (44%) patients, and 1 (11%) patient was diagnosed with the HM prior to the RCC. No patients were treated with cytotoxic chemotherapy or radiation between the diagnosis of RCC and HM. Several unique features were seen in our case series, such as 3 simultaneous cancers in 1 (11%) patient, a splenectomy leading to remission of diffuse large B cell lymphoma without the use of chemotherapy in 1 (11%) patient, chemotherapy and rituximab for lymphoma resulting in a complete response in primary RCC in 1 (11%) patient, and immunotherapy providing an excellent response for primary renal leiomyosarcoma in 1 (11%) patient. CONCLUSION These findings highlight the potential role of immune system dysregulation in patients with the diagnosis of RCC and HM whereby the first malignancy predisposes to the second through an immunomodulatory effect. HM have the potential of being confused with lymph node metastasis from kidney cancer. Lymph node biopsy may be necessary at the time of initial diagnosis or in cases of mixed response to therapy. Long-term medical surveillance is warranted when a patient is diagnosed with RCC or HM. Clinicians should be aware of the higher prevalence of male gender and lymphoid malignancy with concurrent RCC and HM and that either of these conditions may be diagnosed first or they may be diagnosed simultaneously.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Concurrent renal cell carcinoma and hematologic malignancies: Nine case reports

Shields

Kalebasty

2020

WJCO

View full text Add to dashboard Cite

show abstract

“…Our patient had synchronous malignencies. The other case was a 53-year-old male patient diagnosed with RCC 4 years prior to Hodgkin's disease (Ann-Arbor, stage II-B) [3]. And, the third was 69-year-old male patient, diagnosed with multiple myeloma (IgG, κ, stage II-A) and RCC of left nephrectomy specimens, synchronously [3].…”

mentioning

confidence: 99%

“…The other case was a 53-year-old male patient diagnosed with RCC 4 years prior to Hodgkin's disease (Ann-Arbor, stage II-B) [3]. And, the third was 69-year-old male patient, diagnosed with multiple myeloma (IgG, κ, stage II-A) and RCC of left nephrectomy specimens, synchronously [3]. Interestingly, unlike our patient, Choueiri et al reported case series of MM and RCC on the right side with right renal involvement except for one [5].…”

mentioning

confidence: 99%

Renal cell carcinoma and hematological malignancies

Yavaşoğlu

Sargın

2017

Leukemia Research Reports

Self Cite

View full text Add to dashboard Cite

“…W literaturze są opisy innych przypadków współwystępowania PCM i RCC (tab. 1) [5,[9][10][11][12][13][14].…”

unclassified

Nowotwór nerki u pacjentów ze szpiczakiem plazmocytowym — opis dwóch przypadków i przegląd piśmiennictwa

Ożańska¹,

Sobas²,

Olszewska-Szopa³

et al. 2018

Hematologia

View full text Add to dashboard Cite

Szpiczak plazmocytowy (PCM) charakteryzuje się ekspansją nowotworowych komórek plazmatycznych w szpiku. Rak nerkowokomórkowy (RCC) jest rezultatem złośliwej proliferacji komórek nabłonkowych kanalików proksymalnych nefronu i stanowi 95% złośliwych nowotworów nerki. Współistnienie PCM i RCC to zjawisko bardzo rzadkie, istnieją jedynie pojedyncze doniesienia na ten temat. W pracy przedstawiono opis dwóch chorych, u których w trakcie terapii PCM wykryto przypadkowo RCC. Radykalna nefrektomia (we wczesnej fazie choroby) umożliwiła całkowite wyleczenie RCC i kontynuację terapii PCM. Ponadto w artykule omówiono podobne przypadki opisane w literaturze.

show abstract

A coincidence of renal cell carcinoma and hematological malignancies

Cited by 8 publications

References 18 publications

Concurrent renal cell carcinoma and hematologic malignancies: Nine case reports

Concurrent renal cell carcinoma and hematologic malignancies: Nine case reports

Renal cell carcinoma and hematological malignancies

Nowotwór nerki u pacjentów ze szpiczakiem plazmocytowym — opis dwóch przypadków i przegląd piśmiennictwa

Contact Info

Product

Resources

About